Arrowhead Pharmaceuticals, Inc.
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
Granted 7.73M · Bought 200.0K · Sold 3.05M
Bought 102.3K · Sold 1.45M
Granted 1.67M · Sold 784.3K
Granted 970.0K · Sold 416.5K
Granted 1.33M · Bought 15.0K · Sold 725.1K
Granted 415.0K · Sold 306.8K
Granted 135.0K · Sold 86.5K
Granted 75.0K · Sold 40.5K
Granted 261.1K · Sold 131.1K
Granted 75.0K · Sold 13.1K
Granted 145.0K · Sold 3.1K
Granted 75.5K · Sold 18.4K
Granted 354.8K · Bought 655 · Sold 189.0K
Granted 368.8K · Sold 245.8K
Sold 19.3K
Granted 162.3K · Bought 2.3K · Sold 50.6K
Granted 125.3K · Sold 68.7K
Granted 24.6K · Bought 5.4K · Sold 3.0K
Granted 46.2K
Granted 65.7K · Sold 36.5K
Granted 47.4K · Sold 27.1K
Granted 62.8K · Sold 34.2K
Granted 45.0K · Sold 45.0K
Bought 2.0K
Granted 30.8K · Bought 5.0K · Sold 9.5K
Sold 31.3K
Granted 11.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Anzalone Christopher RichardChief Executive Officer, Director · 156 transactions | — | 3.80M | 7.73M | 200.0K | 3.05M |
| Knott David M10% owner · 20 transactions | — | 3.46Mas of Mar 2007 | — | 102.3K | 1.45M |
| Given Bruce DChief Operating Officer · 61 transactions | — | 855.8Kas of Apr 2020 | 1.67M | — | 784.3K |
| Stewart R BruceExecutive Chairman, Director · 1 transaction | — | 511.5Kas of May 2009 | — | — | — |
| O'Brien PatrickCOO · 75 transactions | — | 472.8K | 970.0K | — | 416.5K |
| Myszkowski Kenneth AllenChief Financial Officer · 91 transactions | — | 465.4Kas of Jan 2025 | 1.33M | 15.0K | 725.1K |
| Hamilton James CChief Medical Officer · 62 transactions | — | 227.0K | 415.0K | — | 306.8K |
| San Martin JavierChief Medical Officer · 13 transactions | — | 206.0Kas of Jan 2024 | 135.0K | — | 86.5K |
| Li ZhenSnr. VP, Chem and Non-Clin Dev · 2 transactions | — | 201.7Kas of Jan 2019 | 75.0K | — | 40.5K |
| Leone Peter BrianVP, Strategic Bus. Initiatives · 6 transactions | — | 194.4Kas of Oct 2018 | 261.1K | — | 131.1K |
| Apel Daniel JosephChief Financial Officer · 4 transactions | — | 172.8K | 75.0K | — | 13.1K |
| Frykman Edward WDirector · 7 transactions | — | 148.9Kas of Jan 2018 | 145.0K | — | 3.1K |
| Oliver TracieChief Commercial Officer · 5 transactions | — | 127.1Kas of Jul 2024 | 75.5K | — | 18.4K |
| Given Douglas BDirector · 57 transactions | — | 124.2Kas of Dec 2024 | 354.8K | 655 | 189.0K |
| Perry Michael SDirector · 28 transactions | — | 123.1K | 368.8K | — | 245.8K |
| Hassard JamesChief Commercial Officer · 2 transactions | — | 105.8Kas of Jun 2021 | — | — | 19.3K |
| Ferrari MauroDirector · 21 transactions | — | 69.1K | 162.3K | 2.3K | 50.6K |
| Waddill William D.Director · 25 transactions | — | 56.6K | 125.3K | — | 68.7K |
| Lu HongboDirector · 12 transactions | — | 52.0K | 24.6K | 5.4K | 3.0K |
| Ingram Douglas SDirector · 2 transactions | — | 46.2K | 46.2K | — | — |
| McKenney CharlesDirector · 23 transactions | — | 42.2Kas of Mar 2015 | 65.7K | — | 36.5K |
| Vakiener VictoriaDirector · 13 transactions | — | 37.7K | 47.4K | — | 27.1K |
| Olukotun Adeoye YDirector · 17 transactions | — | 33.6K | 62.8K | — | 34.2K |
| Lewis David L.Chief Scientific Officer · 8 transactions | — | 15.0Kas of Jan 2015 | 45.0K | — | 45.0K |
| Kingsley Joseph Theodore IIIInterim President & CFO · 1 transaction | — | 12.0Kas of Jan 2007 | — | 2.0K | — |
| De Backer MarianneDirector · 18 transactions | — | 4.6Kas of Jan 2023 | 30.8K | 5.0K | 9.5K |
| Bradshaw CurtChief Scientific Officer · 2 transactions | — | 0as of Nov 2020 | — | — | 31.3K |
| Cohen Matthew GregoryDirector · 1 transaction | — | 0 | 11.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -7.46M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.